Скачать или смотреть AdvaMedDx: The Role of Advanced Diagnostics in Cancer Care - Full Briefing

Speakers:
Andrew Fish, Executive Director AdvaMedDx
Amalia Issa, PhD MPH, University of the Sciences, Chair of the Department of Health Policy and Public Health, Director of the Program in Personalized Medicine
Cesar Garcia, President & CEO, IRIS
Walter Koch, PhD, VP, Head of Global Research, Roche Diagnostics
Marcia Horn, President & CEO, International Cancer Advocacy Network (ICAN)


On September 20th, 2012, AdvaMedDx invited diagnostic manufacturers, the cancer research community, and a patient advocate to Capitol Hill briefing in Washington, DC to educate attendees on recent advances in cancer diagnostics that are improving the treatment and management of patients with cancer. Held in conjunction with the House Medical Technology Caucus, this briefing will explore how advanced diagnostics are delivering on the promise of personalized medicine.

Leading medical technology manufacturers are developing new, state-of-the-art diagnostic tests to help physicians and patients make the most informed treatment decisions possible. These tests provide critical information that allow health care providers to detect and diagnose disease earlier, target treatments to the individual patient, utilize more preventative and less invasive treatment options, and manage diseases such as cancer more effectively.

Innovation in molecular diagnostic tests hold great promise for identifying small genetic differences that can often impact diagnosis, prognosis, drug selection, and outcomes for cancer patients. Molecular diagnostic tests can be used to identify a particular existing disease or condition, identify a patient's likelihood of recurrence, and identify genetic variability to allow for more accurate and targeted treatment selection tailored to individual needs.

These advances in diagnostics are helping to improve patient outcomes and save costs by driving more effective decision-making by clinicians and patients.